Introduction: Osteoarthritis (OA) often leads to symptoms such as pain, stiffness and decreased function. OA is treated with a wide range of modalities, both conservatively and surgically. Prolotherapy has been used to treat various musculoskeletal problems and has shown some promise.
Introduction
Osteoarthritis (OA) is an age-related degenerative disease resulting from articular cartilage failure induced by a complex interplay of genetic, metabolic, biochemical and biomechanical factors with secondary components of inflammation leading to degradation of cartilage, bone and synovium. 1 This leads to changes in the joint biomechanics and symptoms such as pain, stiffness and decreased articular function. [2] [3] [4] In industrialized societies, OA is the leading cause of physical disability, increases in health care usage and impaired quality of life. The impact of arthritic conditions is expected to grow as the population both increases and ages in the coming decades. 5 The lifetime risk of symptomatic knee OA is 44.7%, 6 and symptomatic knee disease occurs in~10% of subjects over the age of 55. 7 There is no cure for the knee OA, but there are several therapeutic options that might be helpful in reducing symptoms but do very little in changing the biochemical environment or the degree of degeneration. 8 Conservative treatment usually includes strengthening exercises, 10, 9 lifestyle changes, 11 simple analgesics (non-steroidal anti-inflammatory drugs), 12 different intra-articular injections 13 and supplements such as chondroitin sulphate and glucosamine. 14 For severe pain, opioids can be also prescribed. 15 If conservative management does not produce an adequate reduction of symptoms, there are different surgical options including total joint replacement. Advanced knee OA is the leading cause of total knee arthroplasty (TKA). In 2005 alone, almost 500 000 TKAs were performed in the USA, at a cost exceeding US$11 billion. 16 Prolotherapy (prolo, an abbreviation of proliferation) is an alternative therapeutic procedure used for the management of chronic musculoskeletal conditions. Irritant substances, usually hyperosmolar dextrose or morrhuate sodium, are injected either in an intra-articular fashion or as local injections to the attachment of ligaments and tendons. 17 One mechanism of prolotherapy is that the hyperosmolar glucose solutions hyperpolarize nerves by opening their potassium channels, thus decreasing transmission in nociceptive pain fibres. 18 Additionally, hypertonic solutions are thought to produce an inflammatory response through the recruitment of chemical mediators and growth factors that stimulate local healing of injured extra-and intra-articular tissue. [19] [20] [21] Furthermore, hypotonic solutions are thought to work by blocking transient receptor potential vanilloid type 1, a membrane cation channel that allows influx of Na + and Ca
2+
. 22 Sodium influx is thought to result in action potential and nociception, whereas calcium results in the release of substance P and calcitonin gene-related peptide. 22 Hence, blocking influx of both cations can theoretically minimize neuropathic pain, oedema and tissue intramuscular compartment pressure. 23 However, further definitive evidence regarding basic science remains developmental. The most commonly published indication for prolotherapy is mechanical low back pain. Recently, prolotherapy has been reported to be beneficial in the management of chronic tendinopathies 24 and knee OA. 25 There is an increasing interest in dextrose prolotherapy because of its high safety profile, and potential therapeutic effect in a variety of conditions. 26 Hence, the aim of this systematic review is to provide an evaluation of studies related to the application, effectiveness and safety of dextrose prolotherapy injections to patients with knee OA.
Methods

Strategy for literature search
The systematic review was registered PROSPERO (International Prospective Register of Systematic Reviews) number 37005. Searches of the electronic databases, PubMed, ISI web of science, PEDro and SPORTDiscus, were conducted by F.H. for all papers published from inception through to December 2016 (Fig. 1) .
The search strategy included a wide range of terms for prolotherapy and different terms for OA, aiming for high sensitivity in order to detect all the appropriate literature (Table 1) .
Selecting studies for review
Duplicates were removed and relevant titles were selected from the results. This was followed by retrieval of full articles to decide whether to include them, based on the inclusion and exclusion criteria reported in Table 2 . Studies were excluded if they were pilot studies or unpublished material with <20 participants or if they assessed outcomes other than pain and function (Table 3) . Studies assessing prolotherapy in OA of other joints were excluded if data for the knee joint could not be extracted separately. Reference lists were searched further, and Google Scholar was also used to search cited articles for further relevant articles.
Evaluation of methodological quality
As most of the articles were of an experimental nature, the strength and quality of the evidence was determined using the validated modified Coleman 
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Methodology Score, 27 with a score of >90 considered to be excellent, 80-90 good, 70-80 fair and <70 poor. A modification of this score was completed for use assessing conservative intervention by substituting surgical procedure with non-operative procedure for the purposes of this study. 28 There are 10 separate scoring domains that yield a minimum score of 0 and a maximum score of 100 (Table 4 ). The use of the Coleman Methodology Score modified for conservative therapy (CMS-MCT) attempts to quantify the overall quality of methodology employed in an investigation and provide a relative value on a numerical scale. For the purposes of this study, the score was modified by substituting surgical interventions with conservative treatments, while post-intervention rehabilitation and outcome measurement remained the same. 28 The score is divided into Part A (seven subsections, and only one score may be entered) and Part B (three subsections, and scores may be recorded for each option within each section). Part A is scored by study size, mean follow-up, number of different conservative procedures included in each outcome, design of study, diagnostic certainty, description of conservative procedure given and description of postoperative rehabilitation. Part B is divided into three subsections: (i) outcome criteria (outcome measures clearly defined, timing of outcome assessment is clearly stated, use of outcome criteria that has reported good reliability, use of outcome with good sensitivity); (ii) procedure for assessing outcomes (subjects recruited, investigator independent of surgeon, written assessment, completion of assessment by subjects themselves with minimal investigator assistance); (iii) description of subject selection process (selection criteria reported and unbiased, recruitment rate reported, eligible subjects not included in the study satisfactorily accounted for 100% recruitment). Two senior orthopaedic surgeons completed the process of scoring all the articles independently. Disagreements were defined as a difference of >2 points from the overall score from each individual article, and disagreements were resolved by consensus.
The overall strength of evidence was then assessed by assigning a level of 1-5 according to the criteria proposed by van Tulder et al., 29 depending on the number and quality of studies (Table 5 ).
Statistical analysis
To estimate the effect size of any positive effect, we used Cohen's d values, which have been shown to be a robust tool for assessing magnitude of effects. 
Results
The initial search returned 1297 studies, with 10 articles meeting the inclusion criteria after a process of screening and full-text retrieval (Table 6 ).
Of the 10 articles included, only 1 was a retrospective study. Furthermore, there were no studies that were scored in the excellent or good range for study methodology, two were scored of fair quality (20%) and the rest were of poor quality (80%). The mean CMS-MCT is 65.45 (range 54.00-78.00, standard deviation (SD) 7.6247, 95% CI 60.00-70.90), which falls in the 'poor quality' range. Data from the 10 studies were extracted and summarized in Table 7 .
Population characteristics
The studies reported on a total of 549 patients, of which 345 were females (62.8%) and 204 were males (37.2%). The average age for all participants was 57.7 years. Patients across the 10 studies had varying degrees of symptoms, ranging from mild to severe.
Outcome measures
Studies included had different outcome measures such as the WOMAC score, VAS score, knee pain scale (KPS) score, range of motion measurements, patient satisfaction and radiological assessment.
Summary of results
One study with a population of females showed significant improvement maintained throughout the 24-week period in scores for pain, function and range of motion. Visual analogue score (VAS) for pain was reduced by 45.85% at rest and 44.23% during activity (P < 0.001) and a similar pattern was seen in the Western Ontario and McMaster Universities Arthritis Index (WOMAC), which was reduced by 49.58% at 24 weeks (P < 0.001). 8 Another trial and a follow-up study showed significant improvement in WOMAC scores at 52 weeks and 3.5 years, beyond the minimal clinical important change (35.8% reduction, P < 0.05), and a high patient satisfaction (83%) at 52 weeks. 25, 33 Furthermore, these changes were seen as early as 9 weeks, suggesting both short-and long-term effects. 34 Additionally, when prolotherapy was compared with placebo and an exercise-based treatment group, the prolotherapy treatment group showed more promise at 52 weeks with 50% of participants exceeded the minimum clinically significant change in WOMAC scores, compared with 30 and 24% for the placebo and the exercise groups, respectively.
34
The most recently published investigation showed similar results with the use of 3 months of prolotherapy (with optional treatments at Months 4 and 5), as it resulted in sustained improvement of pain, function and radiological outcomes when compared with physiotherapy alone. 38 Furthermore, the combination of two prolotherapy techniques (Hackett and Lyftgot) resulted in quicker and better improvement in VAS and WOMAC clinical outcomes when compared with use of Hackett technique only. 38 Following the van Tulder criteria for levels of evidence, our results show moderate evidence suggesting that prolotherapy can help achieve significant symptomatic control in individuals with OA. 29 
Effect size calculations
We performed effect size analysis on our included studies. In one study, prolotherapy was superior to saline at 12 weeks ( 38 The difference between Groups 1a and 1b was small, favouring the combination Group (1a). Table 8 shows a summary of effect size values and their respective CIs.
Discussion
We pooled data from electronic databases, published from inception until December 2016, and Group 1: 6 ml 25% intra-articular and 22.5 ml 15% Extra-articular dextrose injections at 1, 5 and 9 wks with asneeded sessions at wks 13 and 17 (n = 30). Group 2: as per Group 1 but Saline is injected instead of dextrose (n = 29) Group 3: home exercises manual and inperson instructions for gradually increased exercise over 20 wks (n = 31).
WOMAC scores improved in all groups at 52 wks (P < 0.01). However, scores for prolotherapy improved more at 52 wks than those receiving saline injections or home exercises (15.3 ± 3.5 vs. 7.6 ± 3.4 and 8.2 ± 3.3 points, respectively). These sig changes were seen as early as 9 wks post-treatment, across all subscales. 50% of dextrose participants exceeded MCIC for WOMAC, compared to 30% and 24% for saline and exercise groups, respectively.
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Continued Extra-articular prolotherapy injections of 15% dextrose (22.5 ml) and intraarticular injections of 25% dextrose (6 ml) at 1, 5 and 9 wks (with asneeded treatments at wks 13 and 17).
WOMAC: 17.2% improvement 4 wks after first injection (7.6 ± 0.2.4 points, P < 0.001), which continued through the 52 wks follow-up, reaching 36.1% (15.9 ± 2.5 points, P < 0.001), which exceeds the MCIC. Analysis showed that females (46-65 yrs) had greater improvement in WOMAC scores. KPS: improvement in both injected (P < 0.001) and non-injected knees (P < 0.05 Extra-articular 15% dextrose and 5% morrhuate sodium injections and a single intra-articular injection of 6 ml 25% dextrose. Treatment delivered at at 1, 5 and 9 wks with as-needed sessions at wks 13 and 17.
Prior-declined: most severe baseline WOMAC (P = 0.02). There was a score change of 42.9% (19.4 ± 7 points, P = 0.05). 75% achieved MCIC. Prior-control: WOMAC score change of 19.5% (12.4 ± 3.5 points, P = 0.002). 55.6% achieved MCIC.
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Continued Both groups reported WOMAC improvement. However, it was more sig in the treatment group at 52 wks (17.6 ± 3.2 vs 8.6 ± 5.0 points, P = 0.05). Near maximal improvement was seen as early as 9 wks in the treatment group. Both groups experienced reduction in MRI-assessed CV (P < 0.05), less so in the treatment group (6.95 vs 7.23%, P < 0.001). Those that lost the least CV in the treatment group had the greatest improvement in pain, suggesting pain-specific diseasemodifying effect.
Reeves et al. Sig more benefit from dextrose injection (P = 0.015) between 0 and 6 Mo. At 12 Mo (6 injections), the dextrosetreated knees improved in pain (44% decrease), swelling (63% decrease), knee buckling frequency (85% decrease), and in flexion ROM (14°i ncrease).
58.5
Grade 2 or more joint narrowing or osteophytic changes KT1000-measured ADD Lateral patellofemoral cartilage thickness and distal femur width both improved sig (P = 0.019 and P = 0.021, respectively). ACL laxity: at 12 Mo, dextrose-treated knees with ACL laxity saw sig improvement in pain, swelling and joint flexion (P = 0.021). 8/13 of those knees were no longer lax as ADD improved by 57% (P = 0.025). found that only 10 of 1297 studies originally identified met our inclusion criteria: they were scrutinized for further evaluation. The Coleman Methodology Score, modified for conservative therapy, was used for evaluation of methodological quality. It showed that evaluated studies fall into the 'poor quality' category overall. In all studies, improvement from baseline was reported. 8, 25, [34] [35] [36] [37] [38] [39] [40] Four studies reported significant improvement comparing with control group. 34, 36, 37, 40 In these studies, dextrose prolotherapy was compared with 0.9% saline and home exercise, 34,36 0.75% lidocaine 37 and with a home exercise programme only. 40 In one study, 39 dextrose prolotherapy was less efficient than erythropoietin injections and similarly efficient as pulsed radiofrequency therapy. To determine efficacy, most studies measured pain reduction, by using VAS, and functional improvement, using the WOMAC score. Some studies also reported high scores in patients satisfaction with dextrose prolotherapy injections. 25, 34, 35, 39 In terms of degree of improvement, one study showed improvement of 17.2% in WOMAC scores 4 weeks after the first injection session, which continued to improve through the 52-week follow-up period to 36.1% (P < 0.001). 33 Several studies showed prolotherapy to be effective. However, most studies did not report analysis on effect size. Cohen's d effect size calculations demonstrated that prolotherapy can exert a large positive effect on WOMAC scores and pain subscale scores as soon as 12 weeks following treatment (2.5, 1.57-3.43), which was maintained to 52 weeks (2.37, 1.14-3.59). 34, 36 This positive effect lasted as long as 2.5 years following treatment. 25 Dextrose prolotherapy can be administered in different ways but there are two key techniques in the literature; the perineural or neurofascial prolotherapy (Lyftogt's technique) and the traditional prolotherapy (Hackett's technique). 22, 41 The perineural method involves injecting dextrose into the subcutaneous tissues to induce a healing response. 22 The traditional Hackett's method involves injecting into the fibro-osseous junction of ligaments or tendons. 41 The perineural method relies on Hilton's law, which states that nerves supplying a joint are the same ones that supply the muscles moving it as well as the skin overlying it. 22 A recent study compared a combination of Hackett's and Lyftogt's techniques with Hackett's only and physiotherapy only. 38 The combination of the two techniques yielded the best improvement, followed by the Hackett's prolotherapy, and then by physiotherapy only. 38 Both the combination and the single technique led to significant clinical and imaging improvement when compared with physiotherapy alone: however, the combination was the best option. 38 This was also supported by our effect size analysis, which showed both techniques to be efficacious. However, the difference between the combination of techniques vs Hackett's technique alone was small, nevertheless still favouring the combination of techniques. There are numerous treatment options for knee OA, documented in systematic reviews and metaanalyses. One of common conservative treatment options was the application of intra-articular steroid injections. Taking into account the considerable heterogeneity between studies, it is not clear whether intra-articular steroid injections provide any clinical benefit after 1-6 weeks. 42 There is highquality evidence confirming that exercise provides short-term effects, lasting for at least 2-6 months after the cessation of treatment. Also, there is moderate evidence confirming improvement after exercise, in physical function, among patients with knee OA. 43 There is no evidence that transcutaneous electrical stimulation is effective for pain relief. Systematic review included only small trials of doubtful quality that hampered final conclusion. 44 There is low-quality evidence that ultrasound might be beneficial for knee OA, but the magnitude of their effect is unknown. 45 There is no evidence that lateral wedge, neutral wedge or knee bracing is efficient in treatment of knee OA. 46 Viscosupplements are an efficient therapeutic option for treatment of knee OA. They are probably beneficial for pain reduction, functional improvement and patient global assessment, especially 5-13 weeks postinjection. 47 There is a small benefit of non-tramadol opioids, which is overshadowed by a significant increase in risk of adverse effects. 15 There is no evidence that any one non-steroidal anti-inflammatory drug (NSAID) is superior to any other if used in equivalent doses. 48 Adverse effects related to NSAIDs use should be also considered, especially if administered over long periods of time.
There are no 'head to head' studies comparing dextrose prolotherapy with any of the mentioned treatment options, except with home programme exercise, 34, 40 where prolotherapy appeared to be more efficient. The great advantage of dextrose prolotherapy is that it is safe, inexpensive, easy to administer, and none of studies included in our systematic review reported any permanent or long lasting adverse effect. We found only one systematic review with a meta-analysis related to dextrose prolotherapy and knee OA. The review included three randomized and one quasi randomized control trials, and confirmed the efficacy of dextrose prolotherapy as well as high safety profile. 49 
Limitation of study
The main limitations are related to small number of studies selected for this systematic review, their small sample size and the lack of high-quality trials, as 80% of the studies identified were of poor quality. There is great heterogeneity among the studies in term of patients characteristic, study design, concentration of injected ingredients, outcome measures, number of injections, time span between each injection and length of post-treatment follow-up. Only one study measured the association between cartilage volume and functional improvement. 36 Dextrose prolotherapy is considered a regenerative type of treatment, which is supposed to change the morphology of injected structures and eventually slow down the degenerative process. None of presented studies was able to confirm such assumption, or to provide explanation for possible mechanism of action. The number and location of injected points is based on palpation rather than on objective radiological investigations, so it is always subject to the personal preference of the injector: this may impact on the treatment outcome.
Furthermore, it would have been beneficial to have been able to calculate odds ratios. Unfortunately, the published articles offered no information on the number of participants who responded vs those who did not respond. This could be a point for future studies to consider, as it will help clinicians to provide statistics that are easy to understand for patients, giving another dimension to effect size.
The strength of this systematic review is that it included a broad database analysis, duplicate study selection, evaluation of methodological quality by two independent reviewers, and comprehensive inclusion and exclusion criteria.
Future studies
Encouraging results, with pain reduction, functional improvement and patient satisfaction, together with high safety profile, provide solid bases for further research that should be focused on standardization of the treatment itself. Optimal volume and concentration of injected substances, the number of treatment sessions and time interval between administration have to be unified. The use of ultrasound may provide more precise assessment of damaged structures and administration of injected substances. RCT comparing dextrose prolotherapy with other injection and noninjection conservative treatments for knee OA would give better insight of the possibility of dextrose prolotherapy being a more wide-spread treatment option. Finally, basic science studies using animal models would provide additional data to help confirm if dextrose prolotherapy can only provide symptom relief or is a truly disease-modifying therapeutic tool.
Conclusion
Dextrose prolotherapy can provide improvement in pain, functional status and patient satisfaction in patients with mild to moderate knee OA, with no long-term or permanent adverse reactions reported. Future research should focus on larger sample size, standardization of treatment protocol and further basic science evidence.
